| 21.55 0.03 (0.14%) | 06-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Fusion Pharmaceuticals Inc. is a clinical-stage oncology enterprise focused on creating precise radiopharmaceutical therapies. The company utilizes its groundbreaking Targeted Alpha Therapies platform, which incorporates its exclusive Fast-Clear linker technology. This innovative system enables the attachment of alpha particle-emitting isotopes to diverse targeting molecules, facilitating the targeted delivery of these potent payloads directly to cancerous growths. Its leading investigational compound, FPI-1434, is currently progressing through Phase 1 clinical trials as a singular treatment for individuals suffering from solid tumors that express the insulin-like growth factor 1 receptor. Beyond this, Fusion is conducting preclinical research into FPI-1434's effectiveness in conjunction with existing checkpoint inhibitors and DNA damage response inhibitors. These studies aim to thoroughly evaluate its anti-tumor effects, ideal dosage regimens, and pharmacological interactions within combination therapies. Furthermore, the firm is moving its earlier-stage candidate, FPI-1966, into clinical evaluation for the management of head and neck, and bladder cancers exhibiting fibroblast growth factor receptor. Fusion Pharmaceuticals also maintains a strategic partnership with AstraZeneca UK Limited, collaborating on the identification, advancement, and market introduction of alpha-emitting radiopharmaceuticals and combined cancer treatments. The company, established in 2014, is headquartered in Hamilton, Canada.
Sat, 28 Sep 2024
AstraZeneca to Buy Fusion Pharmaceuticals for Up to $2.4B as Firm Expands Cancer Pipeline - Investopedia
Tue, 04 Jun 2024
Acquisition of Fusion Pharmaceuticals Completed - PR Newswire
Fri, 31 May 2024
Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement - PR Newswire
Tue, 07 May 2024
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates - PR Newswire
Tue, 19 Mar 2024
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer - PR Newswire
Tue, 19 Mar 2024
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer - AstraZeneca
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|